Global Continuous Bioprocessing Market Size study & Forecast, by Product (Filtration Systems and Consumables, Chromatography Systems and Consumables, Bioreactors, Sterilizers, Centrifuges, Others), by Application (Commercial, Vaccines, mAb production, Rec

Global Continuous Bioprocessing Market Size study & Forecast, by Product (Filtration Systems and Consumables, Chromatography Systems and Consumables, Bioreactors, Sterilizers, Centrifuges, Others), by Application (Commercial, Vaccines, mAb production, Recombinant Protein Production, Cell and Gene Therapy Production, R&D), by End User and Regional Analysis, 2023-2030

Global Continuous Bioprocessing Market is valued at approximately USD 125.6 million in 2022 and is anticipated to grow with a healthy growth rate of more than 22.50% during the forecast period 2023-2030. Continuous bioprocessing refers to a method of manufacturing in the biopharmaceutical industry where the production steps for biological products occur without interruption, as opposed to traditional batch processing. The Continuous Bioprocessing Market is expanding because of factors such as the increasing number of contract development and manufacturing organizations and the rising demand for biopharmaceuticals. In a continuous bioprocessing setup, various stages of the production process, such as cell culture, harvest, purification, and formulation, are connected in a continuous flow rather than being conducted as separate, distinct batches. As a result, the demand for Continuous Bioprocessing has progressively increased in the international market during the forecast period 2023-2030.

Continuous bioprocessing has the potential to reduce overall manufacturing costs by improving resource utilization, minimizing downtime, and optimizing production processes. CDMOs, as service providers, are often focused on delivering cost-effective solutions to their clients. According to Statista, the Contract Development and Manufacturing Organization (CDMO) market accounted for USD 115.5 billion in 2020 and is projected to reach up to USD 223.5 billion by the year 2030. Another important factor that drives the Continuous Bioprocessing Market is the increasing demand for biopharmaceuticals. Continuous bioprocessing can contribute to improved product quality and consistency. Real-time monitoring and control mechanisms enhance the ability to maintain desired product attributes, reducing variability and ensuring high-quality biopharmaceuticals. In addition, as per Statista, the global pharmaceutical market accounted for USD 1.48 trillion in 2022. This represents a marginal gain from 2021 when the market was valued at USD 1.42 trillion. Moreover, the increasing number of contract development and manufacturing organizations and rising demand for biopharmaceuticals are anticipated to create lucrative growth opportunities for the market over the forecast period. However, high capital investments and stringent regulatory requirements are going to impede overall market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Continuous Bioprocessing Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the biopharmaceutical companies forming strategic partnerships and collaborations to expand their market presence in the region. The region’s dominant performance is anticipated to propel the overall demand for Continuous Bioprocessing. Furthermore, Asia Pacific is expected to grow fastest over the forecast period, owing to factors such as bioprocessing technology and partnership expansions, as well as collaborations with key players in biopharma manufacturing in the region.

Major market player included in this report are:
3M Company
Danaher Corporation
Thermo Fisher Scientific, Inc
Merck KGaA
Sartorius AG
Repligen Corporation
Eppendorf SE
Applikon Biotechnology B.V.
Pall Corporation
Bionet Co., Ltd

Recent Developments in the Market:
 In May 2023, 3M has allocated USD 146 million for the enhancement of its biopharma filtration technology. This substantial investment to be directed towards facility enhancements, equipment upgrades, and the recruitment of 60 full-time manufacturing employees in Europe. 3M's cutting-edge filter technology plays a crucial role in bioprocessing, biological, and small molecule pharmaceutical manufacturing. Specifically designed for customers involved in the production of biopharmaceutical drugs, these filters are instrumental in capturing impurities, ensuring the quality and purity of the pharmaceutical products.

Global Continuous Bioprocessing Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Application, End User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product
Filtration Systems and Consumables
Chromatography Systems and Consumables
Bioreactors
Sterilizers
Centrifuges
Others

By Application
Commercial
Vaccines
mAb production
Recombinant Protein Production
Cell and Gene Therapy Production
R&D

By End User
Contract Development and Manufacturing Organizations and Contract Research Organizations
Pharmaceutical and Biotechnology Companies
Academic and Research Institutes

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
3M Company
Danaher Corporation
Thermo Fisher Scientific, Inc
Merck KGaA
Sartorius AG
Repligen Corporation
Eppendorf SE
Applikon Biotechnology B.V.
Pall Corporation
Bionet Co., Ltd

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.